Get started

Biotech

ATAI - 2 potential paths to $5After successfully surpassing the previous swing high with considerable volume, attaining a fresh 52-week peak of $2.85, and witnessing the 50-day moving averages intersecting the 150 and 200 SMAs, ATAI appears poised for a reversal from its downtrend. **Potential Scenarios:** **Scenario 1: Triangular Consolidation (Orange)** ATAI may undergo consolidation within a triangular pattern marked by points A to E. This consolidation phase could indicate a period of indecision in the market as buyers and sellers balance their positions. Typically, triangular patterns suggest that volatility is decreasing, leading to an impending breakout. If this pattern unfolds as expected, a breakout is anticipated around mid-August, potentially triggering a significant move in the stock price. **Scenario 2: Corrective Pattern (Yellow)** Alternatively, the stock might experience a corrective phase represented by an A-B-C pattern. This corrective pattern could indicate a temporary pullback or retracement within the broader uptrend. Such corrections often serve to alleviate overbought conditions and provide an opportunity for new buyers to enter the market. In this scenario, ATAI is expected to establish a higher low by mid-August, reinforcing the bullish momentum and setting the stage for further upside potential. **Price Targets:** Anticipated Fibonacci targets include 1.414 ($4.45) or 1.616 ($5.54) to be achieved by year-end. These Fibonacci extensions are commonly used by traders to identify potential levels of resistance or support based on previous price movements. Additionally, a more ambitious target exceeding $15 within the next few years is also envisaged. This long-term target reflects the potential for ATAI to capitalize on emerging trends and developments within its industry, driving sustained growth and shareholder value over time.
NASDAQ:ATAILong
by joshuashepherd877
2
Gilead Sciences (GILD): Chances in Pharma Beyond TechGilead Sciences (GILD): NASDAQ:GILD We're aiming to diversify our portfolio beyond just tech stocks and the tech sector. We're now focusing on companies in the pharmaceutical industry, such as Gilead Sciences. Analyzing the weekly chart, we observed the largest surge since 2010 for Wave (3). We believe we've also completed Wave (4) at $56.56. The peak was at $123.27, marking our all-time high. This figure is our target for the minimum achievement for Wave 3. It's crucial, and significantly, we anticipate a high selling pressure at this level. Zooming in, we presume we are in Wave 2, expected to conclude between 61.8% and 78.6% retracement. This positions us with a relatively favorable risk-to-reward ratio on the daily chart. Should we drop below this 78.6% retracement level, we could fall back to $56. If that happens, we'll face a problem, potentially falling further for Wave (4) to a maximum of $30. If this decline doesn't materialize, we'll continue to anticipate an upward movement.
NASDAQ:GILDLong
by freeguy_by_wmc
1
Hold it like a rock - Roche, what an opportunity.Hi, 1PERCENT here. Roche Holding, a Swiss multinational biopharma company. It is like the Apple of biopharma. There were only 3 pull backs greater than 30% in the history of the stock. 2002 ~ 2003: -45.33% 2006 ~ 2011: -52.40% 2014 ~ 2018: -30.24% 2022 ~ present: -44.89% It is at the support zone that initiated the +95% move up from 2018 to 2022, and also is testing the trendline connecting the lows in 2003 and 2011. If you live in the US, you might want to have some exposure to Swiss assets (CHF or stocks) and Gold & silver. The US dollar is losing value against the Swiss Francs in the long term. Otherwise, Roche stock price must hold up at the current support zone , otherwise, we are open for a 30+% drop to the next support zone, which will be of course, an absolute bargain. Also, it looks like the previous turnovers from the lows were always accompanied by the MA36 and MA12 crossing (MA12 over MA36) However, we do not have it here yet. So, let's keep an eye on it. That's it. 1PERCENT
SIX:ROGLong
by RVD_1PERCENT
Pfizer (PFE): Shocking Downward Spiral - $11 Target In Sight?Pfizer (PFE): NYSE:PFE At Pfizer, we believe that Wave (2) has not yet completed because Wave B precisely hits the 138% level and structurally does not make sense unless we see a breakthrough of the invalidation zone of the potential subordinate Wave (i) at about $41.62. However, we must form at least a double bottom at $11, which is our minimum expectation for Pfizer. For the downward movement, we need to examine more closely how far it can actually fall, but $11 is our minimum expectation. The only scenario that would make sense here might be a short position for a possible subordinate Wave (iv) between $36.9 and $41.62. Subsequently, for the overarching Wave ((iii)), we expect another decline to a minimum of $22.64 and, in our opinion, a maximum of $9.56. Entering a long position could be too risky over a longer period. For those looking to trade in the short term, there might be a bottom at $25.61, leading up to the potential target zone for Wave (iv). After that, we expect the downtrend to continue, and personally, we are not positioning ourselves long due to the significant risk.
NYSE:PFEShort
by freeguy_by_wmc
VINC Biotech Penny Stock Followup Swing TradesVINC was a penny stock and is now in the near penny category as this biotech stock has had a great run in the past 10 days. On the 30 minute chart, 225 shares are bought at low prices and 125 shares are sold for profit with 100 shares still running as the momentum slows. Overall, the trades where profitable averaging 12% daily in an average trade of 4.5 days. Time and effort in the trade were minimal as the price action was monitored by alerts and notifications as to price to moving average and moving average to moving average crosses as well as dips and peaks of RSI under 40 or over 70 to notify for potential buys or sells in this zig-zag strategy which intended to optimize profit and minimize time and effort in trading.
NASDAQ:VINCLong
by AwesomeAvani
Wuxi Biologics (2269): Incredible long-term opportunity! Wuxi Biologics (2269): HKEX:2269 Wuxi Biologics, a Chinese biotech research company listed on the Hong Kong Stock Exchange, presents a complex investment scenario. It's crucial to note we're dealing with the Hong Kong Dollar, not the US dollar. The comprehensive analysis on the weekly chart suggests that since June 2021, the company has been undergoing a correction defense scenario. This downturn has been so pronounced that the stock might need to reach its origin point at 8.56 HKD to complete the correction cycle of Wave 2 through Wave (Y) in blue. This process is expected to involve an initial surge followed by a downturn. While there's potential for early position building, the decision to do so carries its uncertainties, given regulatory concerns and the stock's unpredictable future. Our strategy is to remain patient, observing how events unfold. Even with a 30% stop-loss threshold, which practically doesn't apply given the upside, we anticipate a minimum 2600% movement for Wave III in red, with the potential to reach an extraordinary 6000% at maximum. Such figures outline the vast upward trajectory expected, not just through Wave 3 but also with an ensuing Wave V. Therefore, we are comfortable waiting and watching for the right entry point. Even if we decide to enter the market at a later stage, we expect that Wuxi Biologics will still offer significant opportunities.
HKEX:2269Long
by freeguy_by_wmc
VINC a speculative biotech penny stock LONGVINC went from 1.5 to 3.0 in less than three hours with 12X relative volume in the afternoon after a month of a slow climb from a news release that really did not amount to much. Insiders are 25% of the shareholders and that may be the story here. This could be manipulation at its finest. I have to wonder how many insiders bought how many shares and when the rug pull. This is a high tight bull flag pattern which typically results in another leg higher of the same magnitude. I suppose that is in clean trading without any manipulation. If this takes off again it might be worth trying with a small position so long as the trader can hit a button to close the full position when the sudden reversal occurs. I will trade this long with a group of moving averages to make alerts for crossing lines and slopes levelling out and see if it can go anywhere.
NASDAQ:VINCLong
by AwesomeAvani
32
Quantum-Si, biotech stock near pivotQuantum-Si NASDAQ:QSI , develops access to the proteome with single-molecule analysis and democratizing to researchers & clinicians Also, "is the world’s first-to-market provider of protein sequencing instruments with core technology based on proprietary time-domain sequencing that enables resolution of amino acids during experiments".- Ark Invest The stock is near finalizing its bottoming process with a pivot buy at $2.50 The Biotech ETF AMEX:XBI already broke out so NASDAQ:QSI is no leader, but still is a good set up.
NASDAQ:QSILong
by dpuleo19
💊 Blueprint Medicines: Positive Momentum and Growth Prospects! 📊 Analysis NASDAQ:BPMC : Financial Performance: 90% YoY growth in net-product revenues from U.S. sales of Ayvakit, a drug for certain cancers. Market Prospects: Positive market response to Ayvakit's unique clinical profile. CEO's Confidence: CEO's confidence in the company's future contributes to its momentum. 📈 Bullish Sentiment: Entry Range: Suggested entry above the $83.00-$84.00 range. Upside Target: Aiming for an upside in the $120.00-$125.00 range. 🌐 Note: Monitor BPMC's ongoing developments and market performance! 📊💹 #BPMC #Biotech #BullishSentiment 💊📈
NASDAQ:BPMCLong
by Richtv_official
Nutrix Therapeutics ( NRIX) has momentum for earnings LONGNRIX , on the 15 minute chart is experiencing increase volatility and volume now two days out from its earnings report. It printed a "big ass" green engulfing candle to finish the week. The MACD with zero lag shows a bullish inflection in the lines On the daily chart, price fell about 25% in 2023. earnings have been both line beats but the negative cash flow remains as a challenge. The volume and volatility show both are heightened in the pre-earnings run- up. . This is a risky earnings play, NRIX does not yet make money like many other young biotechnology companies trying to grow However, because it lost less than forecasted, buyer interest has increased. There is an absence of any options volume and so illiquidity prevents consideration of options trading. I suspect a long trade in shares may gain to $14 targeting the pivot highs of April 23 and November 22 for projected gain upside of about 65% ( stop loss of 2.5%) If earnings disappoint trader expectations and price fades I will stop out with a loss of about 2.5% This makes this long swing trade a projected 2.5 /65 a R:r of 25 which validates it as a conservative trade if taking only 5% or less of buyer power applied to the risk. Biotechnology is expected to be one of the hottest subsectors of 2024. This could be one of them.
NASDAQ:NVAXLong
by AwesomeAvani
LABU / LABD Ratio Anchored VWAP over /under LABU LONGOn the weekly chart a LABU / LABD ratio is plotted with anchored VWAP bands and a volume profile overlaid. I wanted to analyze this to affirm the highest of prospects for the Biotechnology sector for 2024. LABU is triple leveraged Up while LABD is the inverse Down. A good unleveraged biotech ETF is XBI. The chart shows LABU in a VWAP band and breakout through the hohg volume area and then over it beginning early November. Unusually high relative volume and volatility ramped up about the same time. I readily conclude that LABU is the buy right now with the ratio rising. It is a low beat ETF with good range due to the leveraging and high forecasts for 2024. I will make buys on LABU at regular intervals on a 60-120 minute time frame looking for the weekly lows. I will set an alert for a falling ratio on the 3H to daily chart to assess should the supertrend fade. I believe that this will be a safe low risk swing long trade.
AMEX:LABULong
by AwesomeAvani
RYTM Biotech Penny Anti-Obesity LONGRYTM did a 120% run in November and December and then pivoted to start the year. It competes in the anti-obesity drug space which is all the rage right now and has snack food manufactures freaking out. The retrace was a shallow one in a sign of strength finding support at the 0.382 retracement level and then pivoting into a reversal in the past week. The dual TF RSI shows the resurgence of bullish momentum. Earnings were okay, but not great. An FDA approval to add to the mix of meds and lower their price in the competition may send RHYTHM into launch mode. RYTM did 10% today such is the life of highly volatile penny stocks in what is considered to be the likely hottest sector of the year. I will look toward OTM call options for February 16th presently priced at about $200 per contract and a couple of shares shorted to provide some hedging. Looking for 100% in 2-3 weeks. Will close 1/2 the position a few days before upcoming earnings.
NASDAQ:RYTMLong
by AwesomeAvani
1
"NBIX Stock Breaks All-Time Highs, Strong Buy Opportunity!"NBIX Stock Breaks All-Time Highs: A Strong Buy Opportunity Emerges Neurocrine Biosciences Inc. (NBIX) is currently making waves in the stock market as it breaks out of its all-time highs, signaling a promising opportunity for investors. After 14 years of steady upward momentum and price consolidation, NBIX appears poised for further growth, with technical indicators suggesting a bullish trend ahead. The recent surge in NBIX's stock price comes on the heels of strong performance and positive sentiment surrounding the company's products and pipeline. With a focus on innovative treatments for neurological and endocrine disorders, Neurocrine Biosciences has established itself as a leader in the biopharmaceutical industry, attracting investors seeking exposure to high-growth sectors. Technical analysis reveals that NBIX's current breakout is accompanied by the formation of a bull flag pattern, a bullish continuation pattern that often precedes further upward movement. This consolidation phase following a prolonged uptrend suggests that NBIX may be gearing up for another leg higher, providing an attractive entry point for investors. To capitalize on this potential opportunity, traders are advised to monitor the 4-hour time frame closely, watching for confirmation of the breakout and additional upside momentum. A sustained move above the current resistance levels could signal further strength in NBIX's stock price, potentially leading to a retest of its previous all-time highs. Investors considering a position in NBIX should also keep an eye on key support levels and market dynamics, as volatility in the broader market could impact the stock's trajectory. However, with a strong track record of growth and a robust pipeline of innovative therapies, NBIX appears well-positioned to weather any short-term fluctuations and deliver long-term value to shareholders. In conclusion, Neurocrine Biosciences Inc. is breaking out of its all-time highs, presenting a compelling buying opportunity for investors. With 14 years of upward momentum behind it and a bullish pattern forming, NBIX looks poised for further growth in the coming weeks and months. By monitoring the 4-hour time frame and remaining vigilant for additional breakouts, investors can position themselves to capitalize on the potential upside in NBIX's stock price.
NASDAQ:NBIXLong
by UnknownUnicorn2319099